Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with non-small cell lung cancer (NSCLC)

Bogdanova, Natalia; Karaseva, N.; Огнерубов, Н.А.; Golubeva, O.; Weiden, Paul L.

doi:10.1200/jco.2004.22.90140.7133

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Phase I/II study in patients with non-small cell lung cancer, transitional cell, ovarian or colorectal cancer in evaluated the weekly administration of TOCOSOL paclitaxel at doses of 100-120 mg/m 2 in 91 patients. Neuropathy was reported in 22% of patients (19/86) with grade 3 neuropathy been seen after a median of 9 weeks of therapy in 5 patients, 4 of whom had prior therapy with cisplatin [49].…”

Section: Alternate Delivery Strategies For Paclitaxelmentioning

confidence: 99%

Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives

Scripture

Figg²,

Sparreboom³

2006

269

181

View full text Add to dashboard Cite

Abstract:Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol ® , have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.

show abstract

Section: Alternate Delivery Strategies For Paclitaxelmentioning

confidence: 99%